FORA Capital LLC Buys Shares of 45,433 Astera Labs, Inc. $ALAB

Key Points

• FORA Capital LLC acquired a total of 45,433 shares of Astera Labs, Inc. ($ALAB) valued at approximately $2.71 million in the first quarter of the year.
• Astera Labs has seen significant investments from institutional investors, with insiders selling a total of 2,220,416 shares worth over $281 million in the past 90 days.
• Research analysts are optimistic about Astera Labs, with multiple upgrades in ratings, including an upgrade from a "hold" to a "buy," and price targets reaching up to $215.00.

FORA Capital LLC bought a new position in Astera Labs, Inc. (NASDAQ:ALAB - Free Report) in the first quarter, according to its most recent disclosure with the SEC. The firm bought 45,433 shares of the company's stock, valued at approximately $2,711,000.

Several other institutional investors and hedge funds have also recently modified their holdings of ALAB. Sound Income Strategies LLC grew its holdings in shares of Astera Labs by 34.7% in the first quarter. Sound Income Strategies LLC now owns 792 shares of the company's stock valued at $47,000 after purchasing an additional 204 shares during the period. GAMMA Investing LLC boosted its holdings in Astera Labs by 55.7% in the 1st quarter. GAMMA Investing LLC now owns 794 shares of the company's stock valued at $47,000 after purchasing an additional 284 shares during the last quarter. Harbour Investments Inc. boosted its holdings in Astera Labs by 351.7% in the 1st quarter. Harbour Investments Inc. now owns 795 shares of the company's stock valued at $47,000 after purchasing an additional 619 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Astera Labs in the 1st quarter valued at about $48,000. Finally, Hazlett Burt & Watson Inc. boosted its holdings in Astera Labs by 1,670.0% in the 1st quarter. Hazlett Burt & Watson Inc. now owns 885 shares of the company's stock valued at $53,000 after purchasing an additional 835 shares during the last quarter. Institutional investors and hedge funds own 60.47% of the company's stock.

Insider Activity

In related news, Director Stefan A. Dyckerhoff sold 25,000 shares of the company's stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $173.42, for a total transaction of $4,335,500.00. Following the sale, the director directly owned 99,154 shares of the company's stock, valued at $17,195,286.68. This represents a 20.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Sanjay Gajendra sold 91,441 shares of the company's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $183.51, for a total transaction of $16,780,337.91. Following the sale, the chief operating officer directly owned 2,170,877 shares in the company, valued at approximately $398,377,638.27. The trade was a 4.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 2,220,416 shares of company stock worth $281,852,731 over the last 90 days. Company insiders own 12.50% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Wall Street Zen upgraded Astera Labs from a "hold" rating to a "buy" rating in a research report on Saturday, August 16th. Northland Capmk lowered Astera Labs from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 22nd. Evercore ISI upped their price target on Astera Labs from $104.00 to $215.00 and gave the company an "outperform" rating in a research note on Wednesday, August 6th. Needham & Company LLC upped their price target on Astera Labs from $100.00 to $170.00 and gave the company a "buy" rating in a research note on Wednesday, August 6th. Finally, Zacks Research upgraded shares of Astera Labs to a "strong-buy" rating in a report on Tuesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Astera Labs has a consensus rating of "Moderate Buy" and an average target price of $129.13.

Astera Labs Stock Performance

NASDAQ:ALAB opened at $178.56 on Wednesday. Astera Labs, Inc. has a fifty-two week low of $36.85 and a fifty-two week high of $199.47. The company has a 50 day moving average price of $127.26 and a 200 day moving average price of $93.84. The stock has a market capitalization of $29.68 billion, a P/E ratio of 318.86, a PEG ratio of 4.42 and a beta of 1.39.

Astera Labs (NASDAQ:ALAB - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.11. Astera Labs had a net margin of 16.54% and a return on equity of 9.53%. The firm had revenue of $191.93 million for the quarter, compared to the consensus estimate of $172.46 million. During the same period in the prior year, the firm earned $0.13 EPS. The firm's revenue for the quarter was up 149.5% on a year-over-year basis. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. Research analysts forecast that Astera Labs, Inc. will post 0.34 earnings per share for the current fiscal year.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.

Want to see what other hedge funds are holding ALAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astera Labs, Inc. (NASDAQ:ALAB - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.